A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura’s roginolisib
• First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors • Second publication outlines first-in-human (FiH) study results, demonstrating roginolisib’s favorable tolerability profile and encouraging clinical findings in patients with cancer, including metastatic uveal melanoma (mUM)
• Publication of the peer-reviewed papers comes as iOnctura awaits readouts from its two fully-enrolled, randomized Phase II trials of roginolisib in mUM and nonsmall cell lung cancer (NSCLC) Geneva, Switzerland; Amsterdam, The Netherlands; and Cambridge, Massachusetts, USA, October 9, 2026 – iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announced the publication of two peer-reviewed articles in Nature Communications revealing new insights into the novel mechanism and clinical profile of roginolisib, the company’s next-generation, conformationselective PI3Kδ inhibitor.
